ABSTRACT
Members of the Cryptococcus gattii species complex are notorious causes of cryptococcosis as they often cause severe, life-threatening infections. Here we describe a case of a severe disseminated C. deuterogattii infection in a previously healthy patient who was initially treated with amphotericin B, 5-fluorocytosine and fluconazole, which led to a good neurological response, but the infection in the lungs remained unaltered and was not completely resolved until switching the antifungal therapy to isavuconazole. The infection was likely acquired during a one-month stay at the Azores Islands, Portugal. Environmental sampling did not yield any cryptococcal isolate; therefore, the source of this apparent autochthonous case could not be determined. Molecular typing showed that the cultured C. deuterogattii isolates were closely related to the Vancouver Island outbreak-genotype.
Subject(s)
Cryptococcosis , Cryptococcus gattii , Antifungal Agents/therapeutic use , Cryptococcosis/diagnosis , Cryptococcosis/drug therapy , Cryptococcus gattii/genetics , Genotype , Humans , Nitriles/therapeutic use , Pyridines , Salvage Therapy , TriazolesABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Diarrhea/chemically induced , Phosphatidylinositols/antagonists & inhibitors , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Rituximab/therapeutic use , Withholding TreatmentSubject(s)
Diarrhea/chemically induced , Phosphoinositide-3 Kinase Inhibitors , Protein Kinase Inhibitors/adverse effects , Purines/adverse effects , Quinazolinones/adverse effects , Humans , Leukemia, B-Cell/complications , Leukemia, B-Cell/drug therapy , Male , Middle Aged , Protein Kinase Inhibitors/therapeutic use , Purines/therapeutic use , Quinazolinones/therapeutic useABSTRACT
No disponible
